Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective diligently but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire interview which I came away with a poor impression of the business.

Irony of irony, my bad viewpoint of the company has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the therapy as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the know-how as well as connected intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) along with the first new drug application approval ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and multiple indications, it’s this single therapy and a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an active business with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple publications in addition to multiple presentations.

Could it all be smoke and mirrors? That’s a question I have been asking myself through the very start of my interest in this organization. Judging by the multiples of a huge number of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or maybe some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *